ATE197454T1 - Isoxazol- und isothiazolverbindungen, die die kognitiven funktionen verbesseren - Google Patents

Isoxazol- und isothiazolverbindungen, die die kognitiven funktionen verbesseren

Info

Publication number
ATE197454T1
ATE197454T1 AT92912971T AT92912971T ATE197454T1 AT E197454 T1 ATE197454 T1 AT E197454T1 AT 92912971 T AT92912971 T AT 92912971T AT 92912971 T AT92912971 T AT 92912971T AT E197454 T1 ATE197454 T1 AT E197454T1
Authority
AT
Austria
Prior art keywords
isoxazole
cognitive functions
improve cognitive
treatment
isothiazole compounds
Prior art date
Application number
AT92912971T
Other languages
English (en)
Inventor
David S Garvey
George M Carrera Jr
Stephen P Arneric
Youe-Kong Shue
Nan-Horng Lin
Yun He
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE197454T1 publication Critical patent/ATE197454T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT92912971T 1991-05-29 1992-05-28 Isoxazol- und isothiazolverbindungen, die die kognitiven funktionen verbesseren ATE197454T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70692091A 1991-05-29 1991-05-29
PCT/US1992/004631 WO1992021339A1 (en) 1991-05-29 1992-05-28 Isoxazole and isothiazole compounds that enhance cognitive function

Publications (1)

Publication Number Publication Date
ATE197454T1 true ATE197454T1 (de) 2000-11-11

Family

ID=24839628

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92912971T ATE197454T1 (de) 1991-05-29 1992-05-28 Isoxazol- und isothiazolverbindungen, die die kognitiven funktionen verbesseren

Country Status (13)

Country Link
US (1) US5409946A (de)
EP (1) EP0588917B1 (de)
JP (1) JP3153551B2 (de)
AT (1) ATE197454T1 (de)
BR (1) BR1100981A (de)
CA (1) CA2109585C (de)
DE (1) DE69231557T2 (de)
DK (1) DK0588917T3 (de)
ES (1) ES2153360T3 (de)
GR (1) GR3035285T3 (de)
IE (1) IE921690A1 (de)
PT (1) PT100525B (de)
WO (1) WO1992021339A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69325662T2 (de) * 1992-10-23 2000-02-10 Merck Sharp & Dohme Ltd., Hoddesdon Dopamin rezeptor subtyp liganden
US5424444A (en) * 1992-11-25 1995-06-13 Abbott Laboratories Method of preparing enantiomerically-pure 3-methyl-5-(1-alkyl-2(S)-pyrrolidinyl) isoxazoles
US5494680A (en) * 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device
US5723477A (en) * 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5705512A (en) * 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5703100A (en) * 1994-11-10 1997-12-30 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5594011A (en) * 1994-11-10 1997-01-14 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5677459A (en) * 1994-11-10 1997-10-14 Sibia Neurosciences, Inc. Methods for the preparation of modulators of acetylcholine receptors
US5824692A (en) * 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
DE19501022C1 (de) * 1995-01-14 1996-06-05 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von (s)-3-Methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen Salze und Verfahren zu seiner Herstellung
AU5014396A (en) * 1995-03-24 1996-10-16 Japan Tobacco Inc. Diazabicyclo{3.3.1}nonane derivatives and intermediates ther eof, medicinal use of the same, and processes for producing the same
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US5723414A (en) * 1996-01-24 1998-03-03 Rohm And Haas Company 5-aryl-isoxazolinones and herbicidal use thereof
JP4357001B2 (ja) 1996-04-23 2009-11-04 ターガセプト，インコーポレイテッド 中枢神経系障害の予防及び治療のための医薬組成物
US5706829A (en) * 1996-06-06 1998-01-13 Creighton University Method for treating neurocardiogenic syncope
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6166032A (en) * 1997-02-07 2000-12-26 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
KR100589872B1 (ko) 1997-05-30 2006-06-15 뉴로서치 에이/에스 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법
JP2002511068A (ja) 1997-05-30 2002-04-09 ニューロサーアチ・アクティーゼルスカブ アザシクロオクタン及びヘプタン誘導体、その製造方法及びこれを用いて治療する方法
WO1998054182A1 (en) * 1997-05-30 1998-12-03 Neurosearch A/S 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6133002A (en) 1997-09-25 2000-10-17 Dsm N.V. Process for preparing optically active 2-amino-ω-oxoalkanoic acid derivatives
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
BR0316054A (pt) * 2002-11-08 2005-09-20 Mclean Hospital Corp Compostos para tratamento de dependência e privação de tabaco
JP4717444B2 (ja) * 2002-12-20 2011-07-06 ザ マクレーン ホスピタル コーポレーション 睡眠／覚醒サイクルの正規化のための化合物
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
US20050129710A1 (en) * 2003-10-08 2005-06-16 Renshaw Perry F. Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
WO2005037832A2 (en) 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
FR2862647B1 (fr) * 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
US20090215714A1 (en) * 2004-06-10 2009-08-27 Perry Renshaw Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
EP1765075A4 (de) * 2004-06-10 2010-11-10 Mclean Hospital Corp Pyrimidine, wie z.b. uridin; bei der behandlung von patienten mit manisch-depressiver psychose
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
CN103977003A (zh) 2007-04-02 2014-08-13 帕金森氏病研究院 用于降低治疗的副作用的方法和组合物
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
CA2736871C (en) * 2008-09-11 2019-03-12 Catholic Healthcare West Nicotinic attenuation of cns inflammation and autoimmunity
JP2013516497A (ja) 2010-01-11 2013-05-13 ミスリィディオン，インク． 認知増強のための化合物と組成物、製造方法、および治療方法
WO2012033956A1 (en) 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system

Also Published As

Publication number Publication date
DE69231557D1 (de) 2000-12-14
PT100525B (pt) 1999-10-29
JP3153551B2 (ja) 2001-04-09
DE69231557T2 (de) 2001-06-21
IE921690A1 (en) 1992-12-02
PT100525A (pt) 1993-09-30
US5409946A (en) 1995-04-25
EP0588917B1 (de) 2000-11-08
CA2109585C (en) 2000-02-15
CA2109585A1 (en) 1992-12-10
EP0588917A1 (de) 1994-03-30
JPH06508143A (ja) 1994-09-14
BR1100981A (pt) 2000-04-18
EP0588917A4 (de) 1994-04-13
WO1992021339A1 (en) 1992-12-10
GR3035285T3 (en) 2001-04-30
DK0588917T3 (da) 2001-02-12
ES2153360T3 (es) 2001-03-01

Similar Documents

Publication Publication Date Title
ATE197454T1 (de) Isoxazol- und isothiazolverbindungen, die die kognitiven funktionen verbesseren
CA2136075A1 (en) Heterocyclic ether compounds that enhance cognitive function
DE602004020994D1 (de) Piperidinverbindungen und pharmazeutische zusammensetzungen, die diese enthalten
FI931888A0 (fi) Kramploesande cykliska fruktopyranossulfiter -och sulfater
KR950702829A (ko) 신경계 퇴행성 질환의 치료에 유용한 아나바세인 유도체
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2003031435A8 (en) Pyrazole derivatives as glycine transporter inhibitors
GEP20104959B (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
HUT66971A (en) 4-amino-naphthyridine derivatives pharmaceutical compositions containing the same and process for the production of thereof
ATE170530T1 (de) Thiazolidinderivate, ihre herstellung und medikamente, die sie enthalten
PT1270570E (pt) Composto de amida e sua utilizacao
ZA948061B (en) Galanthamine derivatives a process for their preparation and their use as medicaments
DE69120899D1 (de) Neue N-Benzoylprolin-Derivate, Verfahren zur Herstellung und diese enthaltende Arzneimittel
MY132077A (en) Use of n-substituted phenothiazines for the production of medicaments, novel substances and a process for their preparation
KR940018094A (ko) 모르피난의 0-아릴 에테르
ATE109142T1 (de) 1-(pyridinylamino)-2-pyrrolidinone, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel.
ATE181832T1 (de) Pyrido-pyrimidindione, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2355846A1 (fr) Esters de penicillines utilisables comme medicaments
EP0068033A4 (de) N-(4-phenyl-2-thiazolyl)karbamatabkömmlinge, verfahren zu deren herstellung und diese enthaltendes arzneimittel.
SE8503109D0 (sv) Cyclic prodrugs of antiinflammatory oxicams
FR2413362A2 (fr) Nouveaux antidotes de la famille des dichloracetamides
ATE173734T1 (de) Heteroarenylpiperazine, verfahren zu ihrer herstellung und ihre anwendung als medikamente
ES8103082A1 (es) Procedimiento de preparacion de nuevos derivados pirido (3,4-e)-as-triazinos acilados y de sus sales de acicion aci-da de los mismos
GR3015592T3 (en) Pharmaceuticals containing substituted cyclohex-2-en-1-yl-amine derivatives and their use in combatting diseases.
TNSN99235A1 (fr) Derives de 3 -azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee